Good results by Cipla for Q4. Looks like it is well poised til 2025 with both India and USA biz seeing good traction. Only caveat is that FDA issues should be managed well and shouldn’t go out of control.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
